HemaSphere (Aug 2023)
P537: SAFETY AND TOLERABILITY OF AZD0466 AS MONOTHERAPY FOR PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES - PRELIMINARY RESULTS FROM AN ONGOING PHASE I/II TRIAL
- Giovanni Marconi,
- Shukaib Arslan,
- Shaun Fleming,
- Antonio Curti,
- James S Blachly,
- Giovanni Martinelli,
- Matteo Giovanni Della Porta,
- Ashish Bajel,
- Tim Sauer,
- Martina Crysandt,
- Arnaud Pigneux,
- Marina Konopleva,
- Yotvat Marmor,
- Shringi Sharma,
- Nairouz Elgeioushi,
- Emily Rowe,
- Patricia Cheung,
- Ekaterina Jahn,
- Jamal Saeh,
- Raoul Tibes,
- Fathima Zumla Cader,
- Nitin Jain
Affiliations
- Giovanni Marconi
- 1 IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italy
- Shukaib Arslan
- 2 City of Hope National Medical Center, Duarte, United States
- Shaun Fleming
- 3 Alfred Hospital, Department of Clinical Haematology, Melbourne, Australia
- Antonio Curti
- 4 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
- James S Blachly
- 5 The Ohio State University James Comprehensive Cancer Center, Columbus, United States
- Giovanni Martinelli
- 1 IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italy
- Matteo Giovanni Della Porta
- 6 Humanitas Clinical and Research Center – IRCCS, Milan, Italy
- Ashish Bajel
- 7 Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia
- Tim Sauer
- 8 Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
- Martina Crysandt
- 9 Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany
- Arnaud Pigneux
- 10 Hématologie Clinique et Thérapie cellulaire, CHU Bordeaux, Bordeaux, France
- Marina Konopleva
- 11 Albert Einstein College of Medicine, Jack and Pearl Resnick Campus, Bronx, New York, United States
- Yotvat Marmor
- 12 Hematology Oncology R&D, AstraZeneca, Cambridge, United Kingdom
- Shringi Sharma
- 12 Hematology Oncology R&D, AstraZeneca, Cambridge, United Kingdom
- Nairouz Elgeioushi
- 12 Hematology Oncology R&D, AstraZeneca, Cambridge, United Kingdom
- Emily Rowe
- 12 Hematology Oncology R&D, AstraZeneca, Cambridge, United Kingdom
- Patricia Cheung
- 12 Hematology Oncology R&D, AstraZeneca, Cambridge, United Kingdom
- Ekaterina Jahn
- 12 Hematology Oncology R&D, AstraZeneca, Cambridge, United Kingdom
- Jamal Saeh
- 12 Hematology Oncology R&D, AstraZeneca, Cambridge, United Kingdom
- Raoul Tibes
- 12 Hematology Oncology R&D, AstraZeneca, Cambridge, United Kingdom
- Fathima Zumla Cader
- 12 Hematology Oncology R&D, AstraZeneca, Cambridge, United Kingdom
- Nitin Jain
- 13 MD Anderson Cancer Center, Houston, United States
- DOI
- https://doi.org/10.1097/01.HS9.0000969056.80196.f1
- Journal volume & issue
-
Vol. 7
p. e80196f1
Abstract
No abstracts available.